Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
2.800
+0.050 (1.82%)
Nov 22, 2024, 4:00 PM EST - Market closed
Relmada Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for RLMD stock have an average target of 7.50, with a low estimate of 2.00 and a high estimate of 13. The average target predicts an increase of 167.86% from the current stock price of 2.80.
Analyst Consensus: Hold
* Price targets were last updated on Sep 17, 2024.
Analyst Ratings
The average analyst rating for RLMD stock from 2 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $3.5 → $13 | Hold → Strong Buy | Upgrades | $3.5 → $13 | +364.29% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $3 → $2 | Hold → Strong Sell | Downgrades | $3 → $2 | -28.57% | Jun 5, 2024 |
| Mizuho | Mizuho | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +828.57% | Jun 15, 2023 |
| SVB Leerink | SVB Leerink | Buy Maintains $42 → $10 | Buy | Maintains | $42 → $10 | +257.14% | Jan 23, 2023 |
| Goldman Sachs | Goldman Sachs | Strong Buy → Hold Downgrades $8 | Strong Buy → Hold | Downgrades | $8 | +185.71% | Oct 14, 2022 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.70
from -3.28
EPS Next Year
-2.06
from -2.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 31.5M | ||
| Avg | n/a | n/a | 15.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.67 | -1.60 | -1.21 | ||
| Avg | -2.70 | -2.06 | -1.87 | ||
| Low | -2.79 | -2.62 | -3.04 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.